Hormone therapy and cardiovascular risk [1]

JAMA

Volumn 298, Issue 6, 2007, Pages 623-

  Shapiro, Samuel ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

CARDIOVASCULAR RISK; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LETTER; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VAGINA BLEEDING; WOMEN'S HEALTH; AGED; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; FEMALE; MIDDLE AGED; NOTE; RISK;

AGED; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK;

EID: 84888744980     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.6.623-a     Document Type: Letter

References (5)

1. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and years since menopause. JAMA. 2007; 297(13):1465-1477.
2. Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric. 2006;9(6):416-420.
3. Garbe E, Suissa S. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod. 2004;19(1):8-13.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002; 288(3):321-333.
5. Stefanick ML, Anderson GL, Margolis K, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657.